In contrast to CCI-007-treated PER-485 cells [10], global gene-expression analysis of CCI-006-treated PER-485 cells did not reveal a reversal of the MLL-r leukemia target gene signature upon CCI-006 treatment (Table 2). The gene discussed is KMT2A; the disease is leukemia.